PMC:4693303 / 23351-23961 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4693303","sourcedb":"PMC","sourceid":"4693303","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4693303","text":"The research focused on the pharmaceutical treatment of Ebola infection has produced somewhat disappointing results. One candidate drug, TKM-Ebola, after showing promise in primates, has subsequently been demonstrated to be ineffective in treating human Ebola infection.[54] Although the other experimental IgG-based monoclonal antibody-based drug ZMapp has shown good efficacy in primates,[55] there is no compelling evidence that it is effective in humans.[56] In addition, despite a poorly defined safety profile, the drug recently received fast track approval by the Food and Drug Administration (FDA).[57]","tracks":[{"project":"TEST0","denotations":[{"id":"26752867-235-241-1465724","span":{"begin":459,"end":461},"obj":"[\"25972518\"]"}],"attributes":[{"subj":"26752867-235-241-1465724","pred":"source","obj":"TEST0"}]},{"project":"2_test","denotations":[{"id":"26752867-25972518-60482790","span":{"begin":459,"end":461},"obj":"25972518"}],"attributes":[{"subj":"26752867-25972518-60482790","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"TEST0","color":"#93ecab","default":true},{"id":"2_test","color":"#ec9395"}]}]}}